Cargando…

Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?

Diagnosis of de novo autoimmune hepatitis (AIH) after orthotopic liver transplantation (OLT) is challenging especially in the absence of hyper-γ-globulinemia. Circulating autoantibodies are not sensitive nor specific in de novo AIH but when positive increase the diagnostic probability. We report the...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemente, Maria Grazia, Antonucci, Roberto, Mandato, Claudia, Cicotto, Lucia, Meloni, Antonella, Gridelli, Bruno, De Virgiliis, Stefano, Manns, Michael P., Vajro, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723963/
https://www.ncbi.nlm.nih.gov/pubmed/29279846
http://dx.doi.org/10.1155/2017/3563278
_version_ 1783285275496022016
author Clemente, Maria Grazia
Antonucci, Roberto
Mandato, Claudia
Cicotto, Lucia
Meloni, Antonella
Gridelli, Bruno
De Virgiliis, Stefano
Manns, Michael P.
Vajro, Pietro
author_facet Clemente, Maria Grazia
Antonucci, Roberto
Mandato, Claudia
Cicotto, Lucia
Meloni, Antonella
Gridelli, Bruno
De Virgiliis, Stefano
Manns, Michael P.
Vajro, Pietro
author_sort Clemente, Maria Grazia
collection PubMed
description Diagnosis of de novo autoimmune hepatitis (AIH) after orthotopic liver transplantation (OLT) is challenging especially in the absence of hyper-γ-globulinemia. Circulating autoantibodies are not sensitive nor specific in de novo AIH but when positive increase the diagnostic probability. We report the discovery of novel liver microsomal (LM) autoantibodies against CYP-2C19 in a 9-year-old boy with “de novo” AIH developed 7 years after OLT. Graft dysfunction presented with hypertransaminasemia (up to 400 IU/L), while serum γ-globulins remained within the normal range for age. Liver histology and response to high dose prednisone (2 mg/kg/day) with the addition of azathioprine therapy further supported the diagnosis of de novo AIH. Autoantibodies investigation by indirect immunofluorescence (IF) on rodent tissues showed a novel staining pattern involving the pericentral liver zone and sparing the renal tissue. Human but not rat liver proteins immunoblotting allowed us to characterize the novel LM antibodies and to identify CYP-2C19 as human antigen. The finding offers insights into the controversial discussion about autoimmunity versus alloreactivity with regard to the pathogenesis of de novo AIH. Correct information on human versus rat tissue antigens tested by methods other than IF for antibodies detection may have significant implications for the correct diagnosis and management of patients followed up after OLT.
format Online
Article
Text
id pubmed-5723963
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57239632017-12-26 Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis? Clemente, Maria Grazia Antonucci, Roberto Mandato, Claudia Cicotto, Lucia Meloni, Antonella Gridelli, Bruno De Virgiliis, Stefano Manns, Michael P. Vajro, Pietro Biomed Res Int Research Article Diagnosis of de novo autoimmune hepatitis (AIH) after orthotopic liver transplantation (OLT) is challenging especially in the absence of hyper-γ-globulinemia. Circulating autoantibodies are not sensitive nor specific in de novo AIH but when positive increase the diagnostic probability. We report the discovery of novel liver microsomal (LM) autoantibodies against CYP-2C19 in a 9-year-old boy with “de novo” AIH developed 7 years after OLT. Graft dysfunction presented with hypertransaminasemia (up to 400 IU/L), while serum γ-globulins remained within the normal range for age. Liver histology and response to high dose prednisone (2 mg/kg/day) with the addition of azathioprine therapy further supported the diagnosis of de novo AIH. Autoantibodies investigation by indirect immunofluorescence (IF) on rodent tissues showed a novel staining pattern involving the pericentral liver zone and sparing the renal tissue. Human but not rat liver proteins immunoblotting allowed us to characterize the novel LM antibodies and to identify CYP-2C19 as human antigen. The finding offers insights into the controversial discussion about autoimmunity versus alloreactivity with regard to the pathogenesis of de novo AIH. Correct information on human versus rat tissue antigens tested by methods other than IF for antibodies detection may have significant implications for the correct diagnosis and management of patients followed up after OLT. Hindawi 2017 2017-11-27 /pmc/articles/PMC5723963/ /pubmed/29279846 http://dx.doi.org/10.1155/2017/3563278 Text en Copyright © 2017 Maria Grazia Clemente et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Clemente, Maria Grazia
Antonucci, Roberto
Mandato, Claudia
Cicotto, Lucia
Meloni, Antonella
Gridelli, Bruno
De Virgiliis, Stefano
Manns, Michael P.
Vajro, Pietro
Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?
title Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?
title_full Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?
title_fullStr Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?
title_full_unstemmed Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?
title_short Autoantibodies against CYP-2C19: A Novel Serum Marker in Pediatric De Novo Autoimmune Hepatitis?
title_sort autoantibodies against cyp-2c19: a novel serum marker in pediatric de novo autoimmune hepatitis?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723963/
https://www.ncbi.nlm.nih.gov/pubmed/29279846
http://dx.doi.org/10.1155/2017/3563278
work_keys_str_mv AT clementemariagrazia autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis
AT antonucciroberto autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis
AT mandatoclaudia autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis
AT cicottolucia autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis
AT meloniantonella autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis
AT gridellibruno autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis
AT devirgiliisstefano autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis
AT mannsmichaelp autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis
AT vajropietro autoantibodiesagainstcyp2c19anovelserummarkerinpediatricdenovoautoimmunehepatitis